Background-Smoking
M ore than 80 million people have cardiovascular disease in the United States. 1 Although recent data suggest that outcomes are improving in this high-risk population, 2 the overall mortality rate remains quite high, and cardiovascular disease is the number 1 killer in the United States. 1 Considerable research has been directed at improving outcomes in this population. 3 Because of its high associated morbidity and mortality, the influence of smoking in this population remains a major topic of interest and concern. 4 -6 Cigarette smoking has a number of adverse effects that influence the cardiovascular system and overall health. 5 Smoking causes endothelial dysfunction, dyslipidemia, and increased platelet activation, which leads to a prothrombotic state. [7] [8] [9] Smoking causes an increase in insulin resistance and the incidence of diabetes mellitus 10, 11 and is associated with increases in emerging biomarkers, including fibrinogen, factor VII, homocysteine, and C-reactive protein. 12, 13 Thus, a number of mechanisms may help explain the heightened risk of cardiovascular disease in smokers.
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Many reports have consistently demonstrated a significant adverse relationship between smoking and mortality. 14 Risk induced by smoking increases dramatically with the number of cigarettes smoked daily. 15 Data from several reports noted a significant relationship between total and cause-specific mortality in male and female smokers. 16 -18 A recent report from the Nurses Health Study demonstrated that excess vascular mortality may decrease rapidly after smoking cessation, but lung disease mortality may take up to 20 years to demonstrate a decline. 19 The relationship between smoking status, total mortality, and cause-specific mortality in patients with established cardiovascular disease in the current era is less well established.
Recent laboratory data suggest that smoking influences the antiplatelet effect of clopidogrel. 20 Cigarette smoking is an inducer of cytochrome P450 1A2 (CYP1A2), 21 a hepatic enzyme involved in the metabolism of clopidogrel. 22 Clopidogrel has been reported to result in greater inhibition of platelet aggregation in smokers than nonsmokers, 20 which suggests that the pharmacodynamic response to clopidogrel may be modified by smoking. In studies that assessed the variability of platelet response to clopidogrel, smokers were less likely than nonsmokers to be hyporesponders. 23 Whether smoking affects clinical outcomes in patients receiving clopidogrel remains uncertain.
The objectives of the present study were 2-fold: First, to evaluate the relationship between smoking status (current, former, and never) and all-cause, cardiovascular, and cancer mortality in patients with established cardiovascular disease, and second, to investigate the safety and efficacy of clopidogrel versus placebo according to smoking status. We hypothesized that in patients with established cardiovascular disease, current smokers would be at greatest risk for allcause, cardiovascular, and cancer mortality. Because smoking appears to augment the antiplatelet effects of clopidogrel, we postulated that clopidogrel would have a greater benefit and higher bleeding risk than placebo in current smokers than in former smokers or those who had never smoked.
Methods
The design, methods, and primary results of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial have been described in detail previously. 24 To summarize, CHARISMA was a prospective, multicenter, double-blind, randomized, placebo-controlled trial that compared clopidogrel 75 mg/d versus placebo long-term in patients at high risk for cardiovascular events. All patients also received aspirin (75 to 162 mg/d). After a median follow-up of 28 months, clopidogrel was no more effective than placebo in reducing the rate of myocardial infarction (MI), stroke, or cardiovascular death. 25 For the present study, we analyzed the impact of smoking status on mortality, cardiovascular events, and severe or moderate bleeding in subjects with established cardiovascular disease. Additionally, we evaluated the differential treatment effect (interaction) of clopidogrel versus placebo according to smoking status. Because smoking status was also used as an entry criterion for inclusion into the study for patients without established cardiovascular disease, patients without established cardiovascular disease were excluded from the present analysis. We divided the remaining 12 152 patients with established cardiovascular disease into 3 groups, according to smoking status: Current smokers, former smokers, and patients who had never smoked. Current smokers were defined as those who smoked at least 1 cigarette per day during the month before enrollment. Former smokers were defined as those who had smoked at least 1 cigarette per day at any time prior to the month before enrollment. Rates of permanent discontinuation of clopidogrel did not differ by smoking status (current smokers 19.4%, former smokers 18.9%, and neversmokers 18.2%; 2 Pϭ0.51). The median follow-up time was the same as in the main study (28 months) .
We compared the relationship between current smokers and never-smokers, between former smokers and never-smokers, and between current smokers and former smokers for all-cause mortality, mortality subtype, cardiovascular events, and risk of severe or moderate bleeding. In addition, we compared the relative efficacy of clopidogrel versus placebo for all-cause, cardiovascular, and cancer mortality according to smoking status. We also compared the relative safety of clopidogrel versus placebo with regard to severe or moderate bleeding (determined by the GUSTO [Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries] criteria 26 ) according to smoking status. These events were adjudicated by the Cleveland Clinic Clinical Events Adjudication Committee.
Statistical Analysis
All data analyses were performed on the intention-to-treat population. Hypothesis tests were performed with 2-sided tests at the 5% significance level. Baseline characteristics were compared with 2 tests for discrete variables and ANOVA for continuous variables. Adverse outcomes were compared with a 2-sided log-rank test and were plotted with cumulative Kaplan-Meier estimates of the event rates. Hazard ratios (HRs) and their 95% confidence intervals (CIs) were estimated with the Cox proportional hazards model.
Multivariable Cox proportional hazards models were created to assess the relationship of smoking status and adverse outcomes after adjustment for baseline demographic and clinical history variables. Indicator variables of current smoker, former smoker, and neversmoker were created to represent the smoking data. An indicator variable of Europe versus all other locations was created for geographic region. Demographic data and baseline characteristics were entered into a multivariable Cox model for variable selection with bootstrap resampling (500 iterations and a P value criterion of 0.1 for retention). Those variables having a 50% or more probability of retention were considered reliable and were entered into a second Cox model with the model-selection procedure of stepwise selection or backward elimination. The significance level to enter and keep a variable was set at 0.05. These risk factors and the smoking indicator variables met the proportional hazards assumption by plotting the log of the negative log of their estimated survival distribution, log(Ϫlog(S(t))), versus time. The linearity assumption was assessed and satisfied for all continuous variables by plotting the logit of the events against the continuous variable. The selected covariates from the 2 model-selection methods were compared to choose an optimal multivariable Cox model for each individual clinical end point.
Univariable interactions were tested in a Cox proportional hazards model that incorporated terms for randomized treatment, smoking status, and the treatment-by-smoking status interaction to assess whether treatment effect differed for current smokers versus neversmokers and formers smokers versus never-smokers. Multivariable interactions were further analyzed by the addition of covariates of baseline characteristics into the model.
Because the present analysis was exploratory and primarily meant to be hypothesis generating, no adjustments for multiple comparisons were made. All statistical analyses were performed with SAS software (version 9.1.3; SAS Institute, Cary, NC).
Results
Of the 12 152 patients included in the present analysis, 2419 (19.9%) were current smokers, 6260 (51.5%) were former smokers, and 3473 (28.6%) never smoked. The median time of quitting smoking for former smokers was 11 years (range 0 to 69 years, mean 14.3Ϯ13.4 years). Table 1 shows the baseline characteristics of the study participants by smoking status. Compared with never-smokers, current smokers were younger, less frequently female, and more likely to be white. Current smokers were less likely to have a history of hypertension, diabetes mellitus, heart failure, or prior revascularization but more likely to have peripheral arterial disease.
Mortality
All-cause mortality rates differed significantly according to smoking status (current smoker 6.1%, former smoker 4.6%, never-smoker 4.3%; Pϭ0.001; Figure 1 ). After multivariable adjustment, current smokers had an increased risk of all-cause mortality (HR 2.58, 95% CI 1.85 to 3.60, PϽ0.01) compared with never-smokers, whereas the HR associated with former smokers compared with those who had never smoked did not reach statistical significance (HR 1.25, 95% CI 0.93 to 1.68, Pϭ0.14; 
Cardiovascular Disease
The incidence of cardiovascular events (MI, stroke, or cardiovascular death) was 8.4% in current smokers, 7.1% in former smokers, and 7.3% in never-smokers (Pϭ0.05). Compared with those who never smoked, current smokers had an increased adjusted risk of cardiovascular events (HR 
Bleeding
Severe or moderate bleeding occurred in 3.1% of current smokers, 3.0% of former smokers, and 3.3% of never-smokers (Pϭ0.64). After multivariable adjustment, current smokers had a greater risk of severe or moderate bleeding (adjusted HR 1.48, 95% CI 1.09 to 2.00, Pϭ0.01) than never-smokers. No statistically significant increased risk for severe or moderate bleeding was observed for former smokers (HR 1.10, 95% CI 0.87 to 1.40, Pϭ0.42).
Current Versus Former Smokers
After removing all patients who never smoked from the analysis, we performed multivariable adjustments to compare current versus former smokers. Current smokers were at increased risk for all-cause mortality (HR (Figure 2 ).
Clopidogrel
Finally, we assessed whether smoking status had any influence on the effect of clopidogrel. In the overall cohort, rates of all-cause mortality were 4.6% with clopidogrel and 5.0% with placebo (HR 0.91, 95% CI 0.78 to 1.07, Pϭ0.27). A significant interaction existed between current smokers and clopidogrel use for the outcome of all-cause mortality (Pϭ0.018). Among current smokers, clopidogrel was associ- 
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Smoking, Clopidogrel, and Mortalityated with a reduction in all-cause mortality (HR 0.68, 95% CI 0.49 to 0.94). No reduction in all-cause mortality was noted for either former smokers (HR 0.95, 95% CI 0.75 to 1.19) or patients who had never smoked (HR 1.14, 95% CI 0.83 to 1.58). Similarly, a significant interaction existed between current smokers and clopidogrel for the outcome of cardiovascular mortality (P for interactionϭ0.037; Figure 3 ). As would be expected, no significant interaction was noted for cancer mortality (PϭNS). The effect of clopidogrel on reducing cardiovascular events (MI, stroke, or cardiovascular death) did not differ according to smoking status (P for interactionϭNS). Clopidogrel was associated with a nonsignificant reduction in cardiovascular events in current smokers (HR 0.93, 95% CI 0.71 to 1.22), former smokers (HR 0.83, 95% CI 0.69 to 1.00), and never-smokers (HR 0.92, 95% CI 0.72 to 1.17). Although no significant interaction was noted, the benefit of clopidogrel versus placebo on the risk of cardiovascular death or MI was greater in current smokers (HR 0.82, 95% CI 0.58 to 1.15) than in former smokers (HR 0.92, 95% CI 0.74 to 1.15) or those who had never smoked (HR 1.01, 95% CI 0.74 to 1.37).
The relationship between clopidogrel or placebo and severe or moderate bleeding is illustrated in Figure 4 . The risk of severe or moderate bleeding was increased in all smoking categories; however, despite the lack of a significant interaction between smoking and bleeding, the magnitude of the risk of severe or moderate bleeding with clopidogrel appeared to be related to smoking status. Specifically, clopidogrel was associated with a statistically significant increase in the risk of bleeding in current smokers (HR 1.62, 95% CI 1.02 to 2.58, Pϭ0.04). Among those who never smoked, however, the increase in risk associated with clopidogrel was not statistically significant (HR 1.31, 95% CI 0.90 to 1.90, Pϭ0.15).
Discussion
Among patients with established cardiovascular disease, smoking status is a strong independent risk factor for allcause mortality, cardiovascular mortality, cancer mortality, cardiovascular events, and bleeding risk. Current smokers were at higher risk for each end point analyzed than former smokers or those who had never smoked. Interestingly, former smokers had similar outcomes as those who had never smoked, except for higher cancer mortality. These data also indicate that the benefit and risk of clopidogrel may be related to smoking status. Clopidogrel was most effective in reducing all-cause and cardiovascular mortality, while simultaneously causing an increase in the risk of bleeding in current smokers, a finding not observed in former smokers or never-smokers.
We believe the present data have clinical relevance for several reasons. Although smoking is known to influence total and cause-specific mortality in the general population, 16 -18 data in patients with cardiovascular disease are inconsistent. [27] [28] [29] [30] [31] In fact, several reports have described a lower adverse event rate among smokers after an MI or percutaneous revascularization, described as the "smoker's paradox." [27] [28] [29] Nevertheless, despite the younger age and considerably lower risk of current smokers at the time of enrollment in the present study, smoking has a widespread negative effect on their health. The present analysis extends and reinforces evidence of an increase in total and causespecific mortality caused by smoking, as well as the increase in bleeding in a population with established cardiovascular disease.
In the present analysis, former smokers had a risk of all-cause mortality, cardiovascular mortality, and bleeding similar to that for those who had never smoked. In contrast, the risk of cancer mortality remained elevated in former smokers compared with those who had never smoked. These data suggest that the high risk of all-cause and cardiovascular mortality and severe or moderate bleeding subsides after smoking cessation, whereas the risk of cancer mortality persists for a longer period of time. Recent data from the Nurses Health Study are consistent with this idea, with the finding that cardiovascular mortality decreases rapidly on smoking cessation, whereas cancer-related mortality may take up to 20 years to show a decline. 19 The data suggest an important relationship between smoking status and the safety and efficacy of clopidogrel therapy. A formal test of heterogeneity of the treatment effect of clopidogrel on all-cause mortality and cardiovascular mortality was statistically significant, which suggests that the benefit of clopidogrel may not be identical across smoking categories. The present finding indicates that the effect of clopidogrel in reducing all-cause and cardiovascular mortality was greatest among current smokers, and the benefit diminished significantly in former smokers and neversmokers. As expected, the effect of clopidogrel on cancer mortality was neutral, with cancer mortality not modified by clopidogrel use. Surprisingly, the relationship between clopidogrel and cardiovascular events was not significantly modified by smoking. Nevertheless, the apparent *Treatment allocation (clopidogrel vs placebo) was forced into the model. All-cause mortality and cardiovascular mortality were also adjusted for the interaction term between treatment allocation and smoking status.
†Adjusted for model-selected covariates from the pool of age; sex; ethnicity; geographic region (Europe vs all others); body weight; history of heart failure, hypercholesterolemia, hypertension, diabetes mellitus, diabetic nephropathy, transient ischemic attack, MI, stroke, peripheral arterial disease, percutaneous coronary intervention, or coronary artery bypass graft; and baseline medications (aspirin, ␤-blocker, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, oral hypoglycemic). Treatment allocation (clopidogrel vs placebo) was forced into the model. All-cause mortality and cardiovascular mortality were also adjusted for the interaction term between treatment allocation and smoking status. 
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Smoking, Clopidogrel, and Mortalitybenefit of clopidogrel in reducing fatal cardiovascular events in current smokers suggests a real and plausible association. Overall, these data are in accordance with others 32 and support recent ex vivo data that showed greater platelet inhibition by clopidogrel in current smokers than in never-smokers. 20 These data, combined with the present clinical analysis, suggest that factors such as smoking modify the benefit of clopidogrel. Cigarette smoking induces activity of CYP1A2, 21 a hepatic enzyme involved in the metabolism of clopidogrel. Thus, the greater platelet inhibition demonstrated by Bliden and colleagues 20 and the clinical differences observed in the present study may be explained via the induction of CYP1A2. An alternative explanation for the association between smoking and clopidogrel may be explained in part by the lower release of tissue plasminogen activator in current smokers. 8 Current smokers with impaired endogenous fibrinolysis may benefit the most from antiplatelet therapy, an observation noted in thrombolytic therapy and termed the "smoker's paradox." 33 Because clopidogrel is known to increase bleeding, we evaluated whether smoking would modulate the excess bleeding risk with clopidogrel. Although no significant interaction was detected for bleeding risk and smoking, current smokers had the greatest risk of bleeding with clopidogrel use. This excess risk was attenuated in a stepwise fashion among former and current smokers.
Study Limitations
There are several important limitations of the present analysis. First, this post hoc subgroup analysis should be considered hypothesis generating. The present analyses of smoking status are based on a single baseline determination that may have changed over the study period; we did not have data on smoking after enrollment. However, misclassifications of smoking status would probably have attenuated the true association between current smokers and adverse events; thus, these results may represent an underestimate of the risk associated with current smoking.
Conclusions
Among patients with established cardiovascular disease, current smokers are at increased risk for all-cause, cardiovascular, and cancer-specific mortality, cardiovascular events, and severe or moderate bleeding. These data also suggest that the benefit and risk of clopidogrel may be modified by smoking status, thus providing additional evidence to support the hypothesis that the antiplatelet effect of clopidogrel may be enhanced in current smokers.
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